



An Emerging Producer of
Canadian Medical Marijuana

February 2017

Forward Looking Statement

This presentation and its appendices (together the "Presentation") have been prepared and delivered by DelShen Therapeutics Corp. ("DelShen" or the "Company"). The Presentation and its contents are strictly confidential and may not be reproduced or redistributed, in whole or in part, to any other person than the intended recipient.

The Presentation is prepared for discussion purposes only. The Presentation does not constitute, and should not be construed as, any offer or invitation or recommendation to buy or sell any of the securities issued by the Company and does and will not constitute or form or be part of any offering material.

The Presentation contains information which has been sourced from third parties believed to be reliable, but without independent verification. The Presentation contains certain forward-looking statements relating to the business, financial performance and results of the relevant issuers and/or industries and markets. These statements may contain words as "will", "expects", "anticipates", "believes", "estimates" and words of similar import. Any forward-looking statements and other information contained in this Presentation, including assumptions, opinions and views cited from third party sources are solely opinions and forecasts which are subject to risks, uncertainties and other factors that may cause actual events to differ materially from any anticipated development. As such by the nature of any forward looking statement, relying on such statements involves risk.

This Presentation has not been reviewed or registered with any public authority, stock exchange or regulated market place, hereunder the Toronto Stock Exchange. The shares of the Company have not and will not be registered under the U.S. Securities Act or any state securities laws, and may not be offered or sold within the United States, or to the account or benefit of U.S. Persons.

No part of this document may be copied or duplicated in any form or by any means or redistributed without the written consent of the Company. The distribution of this Presentation is in certain

jurisdictions is restricted by law, including (but not limited to) USA, Canada, Japan, Australia and Hong Kong. Persons into whose possession this Presentation may come are required to inform themselves about and to comply with all applicable laws and regulations in force in any jurisdiction in or from which it invests or receives or possesses this Presentation and must obtain any consent, approval or permission required under the laws and regulations in force in such jurisdiction.

By attending or receiving this Presentation you acknowledge that you will be solely responsible for your own assessment of the information herein, the market and the market position of the Company and the relevant securities and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of any relevant investments. Neither DelShen nor any subsidiary undertakings or any such person's affiliates makes any undertaking, representation or warranty (express or implied) as to the accuracy or completeness of the information (whether written or oral and whether or not included in this Presentation) concerning the matters described herein. Neither DelShen nor any subsidiary undertakings or any such person's affiliates accepts any liability whatsoever as to any errors, omissions or misstatements contained herein and, accordingly, neither DelShen nor any subsidiary undertakings or any such person's affiliates, officers, employees, accepts any liability whatsoever arising directly or indirectly from the use of this Presentation or the information included herein.

The Presentation speaks and reflects prevailing conditions and views as of January 2015. It may be subject to corrections and change at any time without notice. Neither DelShen nor any subsidiary undertakings or any such person's affiliates intend to, and neither the delivery of this Presentation or any further discussions with any recipient shall, under any circumstances, not create any implication that the Company assumes any obligation to, update or correct the information herein. Nor is this Presentation an implication that there has been no change in the affairs of the Company since such date.

BEST IN CLASS

Medical Marijuana Opportunity

- ACMPR regulations are estimated to create new industry worth over \$1 billion/year
- Delshen brings two of the world's foremost experts in growing highest quality medical marijuana, clinically proven genetics, and years of patient history from Holland
- Pharmaceutical marketing approach that does not merely sell to doctors, but also educates and builds long term relationships.
- Refurbished Ministry of Natural Resources growing facility, with access to plentiful and inexpensive power, completed.
- Health Canada Inspection has taken place with issuance of license to cultivate expected shortly.
- 3-phase build-out will ultimately produce 13,440kg, \$102MM revenue, and \$67MM free cash flow per year.

The Game Changer

- Private industry now the supplier of medical Marijuana
- Must be produced in licensed, regulated, and secure facilities
- Export of medical marijuana is also permitted

Large New Market Opportunity

- 450,000 potential new customers
- \$1.3 billion in annual sales by 2024
- Market size to grow by 17x over next 10 years
- Numerous licensed providers likely to have market caps well above \$100mm in next few years.
- Canada on the path to full legalization






Superior Product



- Partnered with Marcel de Wit: Founder and was exclusive producer of pharmaceutical quality marijuana in the Netherlands.
- Track record of selling pharmaceutical grade marijuana and Chairman of Maripharm
- Delshen holds a perpetual exclusive right to produce and sell the de Wit strains in Canada
 - includes 3 strains registered with the EU's Community Plant Variety Office and seven other established strains to be provided by Maripharm
 - de Wit strains have 10+ years of medical use with understood applications for various indications
 - Maripharm is one of only two ISO 9000 and GMP certified medicinal marijuana growers in the world

Medicinal Grade Cannabis (MGC) #1001, 1004 and 1006 registered with the EU's Community Plant Variety Office.





Endocannabinoid System

The Human Endocannabinoid System

CBD, CBN and THC fit like a lock and key into existing human receptors. These receptors are part of the endocannabinoid system which impact physiological processes affecting pain modulation, memory, and appetite plus anti-inflammatory effects and other immune system responses. The endocannabinoid system comprises two types of receptors, CB1 and CB2, which serve distinct functions in human health and well-being.

CB1 receptors are primarily found in the brain and central nervous system, and to a lesser extent in other tissues.

Receptors are found on cell surfaces



THC
Tetrahydrocannabinol



CBD
Cannabidiol



CBN
Cannabinol



CB1
CBD does not directly "fit" CB1 or CB2 receptors but has powerful indirect effects still being studied.



CB2 receptors are mostly in the peripheral organs especially cells associated with the immune system.



Hippocampus
Basal ganglia
Spinal cord

Indirect Effects
Opiate
5HT
GABA
NMDA
Glutamate



Endocannabinoid System

- These receptors in the brain and in other nervous system tissues are simply called CB1 receptors.
- CB2 receptors have been identified primarily in certain cells of the immune system.
- Most of the cognitive influences of Cannabis can be attributed to CB1 receptor activation.
- CB2 receptors, in contrast, appear to be responsible for for the ability of cannabinoids such as THC (tetrahydrocannabinol) and CBD (cannabidiol) to reduce inflammation and pain.

Risk of Use & Harm Reduction

Overview of Dependence Rates
(INSTITUTE OF MEDICINE REPORT, 1999)

CANNABIS	9%	OPIATES	23%
ALCOHOL	15%	NICOTINE	32%
COCAINE	17%		


Do these numbers surprise you ?



Research

HASHIBE ET AL. 2006

- Large scale study of heavy marijuana smokers
- Assess lung cancer risk
- Heavy users = 22, 000+ joints/lifetime
- Moderate use = 11, 000 – 22,000/lifetime
- 2 pack/day cigarette smokers saw 20 fold increase in lung cancer risk
- No elevation in risk in either marijuana group, even the heaviest users



CANNABIS AMERICANA

U. S. P.

Physiologically Tested

OUR American variety is the answer to the question which has so long troubled manufacturers.

With our material a finished product can be turned out at a reasonable cost.



IT is no longer necessary to depend on the foreign variety which is of high cost and slightly superior. The uncertainty of further supplies of it is another factor favoring the American product.

J. L. HOPKINS & CO., 100 William St., New York

The [Ebers Papyrus](#) (ca. 1550 BCE) from Ancient Egypt has a prescription for medical marijuana applied directly for inflammation.

Clinical Use

- Oncologists and pain specialists readily agree that cannabis can
 - reduce chronic pain,
 - eliminate nausea,
 - stimulate appetite
 - immediate-acting muscle relaxant
 - Decreases spasms
 - Relaxes smooth muscle of bladders
- Cannabis is also an anti-inflammatory and an immunomodulation agent
- Growing number of journal articles attesting to the cancer-fighting properties of directly applied cannabinoids to cancer cells, including malignancies affecting the brain (gliomas), breast, prostate, lungs, pancreas, skin, and immune system (Sarfarez et al. 2008)



Cannabinoids & Neuroprotection


MS (Multiple Sclerosis)

- Chronic relapsing neuro-degenerative disease produces widespread demyelination of nerve cells in brain and spinal cord
- Cannabis reduces MS-related symptoms including pain, muscle spasticity, depression, fatigue, and incontinence are well established in medical literature (Baker et al. 2000, Brady et al. 2004)
- Many MS patient organizations, including the MS Society of Canada and Britain, endorse the use of cannabis to treat MS
- The prescription use of a cannabis-based medicinal extract has been approved in Canada for the treatment of MS-associated neuropathic pain



Different Products to Treat Different Indications

Each medical marijuana strain contains differing concentrations of THC and Cannabidiol (CBD), the main active chemical compounds found in marijuana



MGC 1001®	50/50 % Indica / Sativa	11.0 % THC
MGC 1002	15/85 % Indica / Sativa	20.0 % THC
MGC 1003	25/75 % Indica / Sativa	22.5 % THC
MGC 1004®	80/20 % Indica / Sativa	17.5 % THC
MGC 1005	40/60 % Indica / Sativa	18.0 % THC
MGC 1005	40/60 % Indica / Sativa	18.0 % THC
MGC 1006®	20/80 % Indica / Sativa	15.5 % THC
MGC 1007	80/20 % Indica / Sativa	19.0 % THC
MGC 1008	55/45 % Indica / Sativa	15.0 % THC
MGC 1009	85/15 % Indica / Sativa	18.0 % THC
MGC 1010	75/25 % Indica / Sativa	17.0 % THC

Source: Raphael Mechoulam, et al. "Non-Phyco-tropic Plant Cannabinoids: New Therapeutic Opportunities from an Ancient Herb", Trends in Pharmacological Science, 1-13 (2009)

Board of Directors



Hon. Martin Cauchon

C.P., LL.M. IAS.A


- Held many pivotal federal cabinet positions, including Secretary of State, Minister of National Revenue, Minister of Justice and Attorney General of Canada. Introduced legislation decriminalizing marijuana in 2003 as Justice Minister
- Currently counsel at the DS Welch Bussières group and also leads the China Group sector.
- LL.M., University of Exeter (U.K.), 1991, LL.L., University of Ottawa, 1984, Barreau du Québec, Canadian Bar Association



Alain Dubuc

O.C.

- Journalist at La Presse since 1976 as an economic columnist and Editor In Chief
- Winner of many awards including the National Newspaper Award (2001), and the Hyman Solomon Award (2008)
- Officer of the Order of Canada



Lieutenant-General Jim Gervais

(Retired)

- Former Army Commander in the Canadian Armed Forces
- Served as a public servant for 12 years as Assistant Deputy Minister to Canada's Governor General
- Chairman of the Board of Commissionaires Ottawa, a large, not-for-profit security firm employing military and RCMP Veterans

Board of Directors



Martin R. Shefsky
Executive Director

- Over 20 years management experience with existing and start-up companies in Canada, and Founder of DelShen
- Former Chairman of Northern Gold Mining, founder and director of Regis Resources from 1997 to 2005
- Background in development, sales and marketing and experience in a wide spectrum of commercial ventures



Dr. Barry Kurtzer
M.D., MRO (AAMRO), President, CEO & Medical Director

- Has held senior medical advisory positions for a number of companies and agencies in Canada
- Former President and CEO of medical clinics and the first public mail order pharmacy in Canada
- Has directed delivery of comprehensive Alcohol and Drug Testing Services and Occupational Health Programs to more than 6,000 Canadian business and their workers since 1977
- Graduated from the Faculty of Medicine (U. Toronto) in 1975, holds Medical Review Officer (MRO) specialist certification through the American Association of Medical Review Officers (AAMRO)

Advisors



Boaz Wachtel
Technical Consultant

- A Medical cannabis pioneer in Israel, who lectures on medical cannabis in Israel and abroad
- A founding member of the Israeli Foundation for Drug Law Reform in 1994 and an Initiator of the Medical Cannabis efforts in Israel, beginning in 1996
- Since 2001, he has been a Member of the Steering Committee of ENCOD (European Coalition for Just and Effective Drug Policies)
- Since 2006, Mr. Wachtel has been a Member of the Board of the Israeli AIDS committee, the leading anti-AIDS NGO in Israel



Marcel de Wit
Technical Consultant

- A pioneer in the field of manufacturing pharmaceutical grade cannabis
- Currently Chairman of the non-profit organization Maripharm in the Netherlands, who was the sole Dutch supplier of medical grade cannabis until 2003
- Maripharm has three strains of Medicinal Grade Cannabis (MGC) granted protection under the Community Plant Variety Office of the European Union
- In 2003, Maripharm received an ISO 9001 certificate for management quality, and in 2007, Maripharm received GMP certification for the production for Cannabis-drops